Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27708247)

  • 1. Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.
    Pradhan S; Mahajan D; Kaur P; Pandey N; Sharma C; Srivastava T
    Oncotarget; 2016 Nov; 7(44):71841-71855. PubMed ID: 27708247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
    Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
    Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors.
    Pandey N; Tyagi G; Kaur P; Pradhan S; Rajam MV; Srivastava T
    Cell Physiol Biochem; 2020 Aug; 54(4):748-766. PubMed ID: 32809300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.
    Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L
    Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
    Cai Y; Yan X; Zhang G; Zhao W; Jiao S
    Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
    Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
    PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
    Pisano C; Vesci L; Milazzo FM; Guglielmi MB; Foderà R; Barbarino M; D'Incalci M; Zucchetti M; Petrangolini G; Tortoreto M; Perego P; Zuco V; Orlandi A; Passeri D; Carminati P; Cavazza C; Zunino F
    Clin Cancer Res; 2010 Aug; 16(15):3944-53. PubMed ID: 20562210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
    Lee EJ; Lee BB; Kim SJ; Park YD; Park J; Kim DH
    Int J Oncol; 2008 Oct; 33(4):767-76. PubMed ID: 18813790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
    Takai N; Ueda T; Nishida M; Nasu K; Narahara H
    Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditions.
    Lee JG; Shin JH; Shim HS; Lee CY; Kim DJ; Kim YS; Chung KY
    Respir Res; 2015 Nov; 16():138. PubMed ID: 26553068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
    Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
    Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
    Liu L; Sun X; Xie Y; Zhuang Y; Yao R; Xu K
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29945926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer.
    Wang M; Li G; Yang Z; Wang L; Zhang L; Wang T; Zhang Y; Zhang S; Han Y; Jia L
    Oncotarget; 2017 Jan; 8(5):8083-8094. PubMed ID: 28042952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
    Shin DH; Choi YJ; Park JW
    Cancer Res; 2014 Jan; 74(1):298-308. PubMed ID: 24240701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.
    Lai SL; Perng RP; Hwang J
    J Biomed Sci; 2000; 7(1):64-70. PubMed ID: 10644891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.